Keeping Track: Dueling 'Breakthroughs' For Peanut Allergy

The latest drug development news and highlights from our FDA Performance Tracker.

The list of "breakthrough" therapy designations continues to grow as FDA deems a second peanut allergy desensitization treatment worthy of the status, while Keeping Track also notes new submissions for autoimmune disease, acromegaly and migraine.

FDA has granted its second "breakthrough" therapy designation for a peanut allergy treatment in three months, setting the stage for...

More from Clinical Trials

More from R&D

Cancer Drug Combos: US FDA Guidance Offers Options Beyond Factorial Trials

 
• By 

Acknowledging the risks and limitations of factorial designs, draft guidance outlines how sponsors might employ external data, such as registries or patient-level real-world data, for combination cancer therapies.

US FDA Rare Disease Hub RISEs After Slow Start

 

The first “Rare disease Innovation, Science and Exploration (RISE) meeting to discuss the choice of control arms for studies in small populations will be Sept. 3 after plans were delayed by ongoing changes at the FDA.

GDPR Clarity For Pharma: Industry Code Nears EU-Wide Approval After Six-Year Journey

 
• By 

The pharmaceutical industry is edging closer to EU-wide clarity on how the bloc’s data privacy rules can be applied consistently to clinical trials and pharmacovigilance activities.